TransCode Therapeutics, Inc. Board of Directors

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Ms. Susan Duggan M.B.A., R.N.

Ms. Susan Duggan M.B.A., R.N.

Senior Vice President of Operations

Mr. Thomas A. Fitzgerald M.B.A.

Mr. Thomas A. Fitzgerald M.B.A.

Interim CEO, CFO, President, VP of Administration & Director

Dr. Anna Moore Ph.D.

Dr. Anna Moore Ph.D.

Co-Founder, Scientific Advisor & Member of Scientific Advisory Board

Dr. Zdravka Medarova Ph.D.

Dr. Zdravka Medarova Ph.D.

Co-Founder & Chief Scientific Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.